On April 2, 2019, the Alzheimer’s Drug Discovery Foundation (ADDF) announced that its Diagnostics Accelerator is seeking to fund the development of digital tools to capture quantifiable biomarkers for Alzheimer's disease and related dementias. Digital biomarker tools may allow the remote capture of changes in a patient's physical and mental status at various stages of Alzheimer's disease; the information gathered can span cognitive assessments to motor ability to sleep disruptions. Letters of intent are due by June 7, 2019, and an invited full proposal is due by August 16, 2019. Funding provided through this initiative is . . .